Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients

Trulicity gets FDA nod for reducing CV risk in type 2 diabetes patients

Source: 
Pharmaceutical Business Review
snippet: 


Eli Lilly and Company (Lilly) has been granted approval for Trulicity (dulaglutide) from the US Food and Drug Administration (FDA) for reducing the risk of major adverse cardiovascular events (MACE) in adults having type 2 diabetes.